Clinical trial
A Randomized, Double-blind, Dose-escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, be Consistency and Food Effects of LY03021 Tablets in Healthy Subjects
NCT07371065 is registered in ClinicalTrials.gov with Luye Pharma Group Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Dose-escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, be Consistency and Food Effects of LY03021 Tablets in Healthy Subjects
- Lead sponsor
- Luye Pharma Group Ltd.
- Phase
- Phase 1
- Overall status
- Enrolling by invitation
- Start date
- October 28, 2025
- Completion date
- April 30, 2026
- Enrollment
- 98 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.